1. Home
  2. NUVB vs NSP Comparison

NUVB vs NSP Comparison

Compare NUVB & NSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • NSP
  • Stock Information
  • Founded
  • NUVB 2018
  • NSP 1986
  • Country
  • NUVB United States
  • NSP United States
  • Employees
  • NUVB N/A
  • NSP N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • NSP Professional Services
  • Sector
  • NUVB Health Care
  • NSP Consumer Discretionary
  • Exchange
  • NUVB Nasdaq
  • NSP Nasdaq
  • Market Cap
  • NUVB 1.6B
  • NSP 1.7B
  • IPO Year
  • NUVB N/A
  • NSP 1997
  • Fundamental
  • Price
  • NUVB $4.62
  • NSP $32.94
  • Analyst Decision
  • NUVB Strong Buy
  • NSP Hold
  • Analyst Count
  • NUVB 7
  • NSP 3
  • Target Price
  • NUVB $8.86
  • NSP $47.67
  • AVG Volume (30 Days)
  • NUVB 9.4M
  • NSP 816.0K
  • Earning Date
  • NUVB 11-03-2025
  • NSP 11-03-2025
  • Dividend Yield
  • NUVB N/A
  • NSP 7.31%
  • EPS Growth
  • NUVB N/A
  • NSP N/A
  • EPS
  • NUVB N/A
  • NSP 0.45
  • Revenue
  • NUVB $26,748,000.00
  • NSP $6,757,000,000.00
  • Revenue This Year
  • NUVB $283.17
  • NSP $5.06
  • Revenue Next Year
  • NUVB $340.98
  • NSP $5.35
  • P/E Ratio
  • NUVB N/A
  • NSP $73.38
  • Revenue Growth
  • NUVB 1137.19
  • NSP 3.19
  • 52 Week Low
  • NUVB $1.54
  • NSP $32.65
  • 52 Week High
  • NUVB $5.55
  • NSP $95.98
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 55.23
  • NSP 18.86
  • Support Level
  • NUVB $4.45
  • NSP $33.43
  • Resistance Level
  • NUVB $5.17
  • NSP $46.68
  • Average True Range (ATR)
  • NUVB 0.44
  • NSP 2.33
  • MACD
  • NUVB -0.05
  • NSP -1.18
  • Stochastic Oscillator
  • NUVB 44.17
  • NSP 1.26

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

Share on Social Networks: